United States Patent 10,195,183: What the Claims Actually Cover and Where the Landscape Creates (or Removes) Value

US Patent 10,195,183 claims methods for treating chronic idiopathic urticaria (CIU) using dexpramipexole. The claim set is broad on indication and dosing ranges, but it also locks in a specific active (dexpramipexole) and then adds narrower “dose form” and “regimen” hooks that can affect enforceability and design-around risk.

What do the independent and dependent claims cover?

Core treatment claim (Claim 1)

Claim 1 is a method claim: treat chronic idiopathic urticaria by administering a therapeutically effective amount of dexpramipexole to a subject in need.

This is the pivot: enforceability turns on whether accused activity (a) treats CIU or a claim construction that reads on CIU, and (b) administers dexpramipexole at an amount that is “therapeutically effective.”

Dose range scaffolding (Claims 2, 3)

Claim 2 defines dose bands (per day) selected from:
- about 1 mg to 1,000 mg/day
- about 50 mg to 600 mg/day
- about 150 mg to 300 mg/day
Claim 3 defines minimum daily dosing:
- at least about 150 mg
- at least about 300 mg
- at least about 600 mg

This structure creates multiple compliance “entry points” for enforcement: a defendant dose that lands anywhere in a dependent claim’s selected range can be argued to fall within a claimed embodiment.

Dosing frequency and scheduling (Claims 4, 5, 16, 17)

Claim 4 limits “administering” to one of:
- fraction of total therapeutically effective amount two or more times/day
- half amount twice/day
- therapeutically effective amount every 12 hours
Claim 5 narrows further to:
- about 150 mg twice/day
Claim 16:
- about 75 mg twice/day
Claim 17:
- about 300 mg twice/day

These dependent claims matter because they let the patentee argue infringement against specific clinical regimens, not just daily dose totals.

Combination therapy / induction step (Claims 6–15)

Claim 6 adds an induction step in which a therapeutic agent decreases:
- mast cell levels and/or activation,
- basophil levels and/or activation,
- eosinophil levels and/or activation,
- alone or in combination.
Claim 7 provides a broad agent genus list including multiple immunomodulators and biologics across pathways:
- glucocorticoids/corticosteroids
- NSAIDs
- tyrosine kinase inhibitors (including imatinib via Claim 8)
- anti-cytokine monoclonals and receptor monoclonals
- IL-5, IL-5 receptor, IL-13, IL-13 receptor, IL-4, IL-4 receptor
- anti-IgE monoclonal antibody (omalizumab via Claim 13)
- TNF-alpha inhibitors (multiple via Claim 14)
- fusion proteins (etanercept via Claim 15)
- plus “combination thereof”
Claims 8–15 fix particular exemplars:
- Imatinib (Claim 8)
- Mepolizumab / reslizumab (Claim 9)
- Benralizumab (Claim 10)
- Lebrikizumab (Claim 11)
- Dupilumab (Claim 12)
- Omalizumab (Claim 13)
- Infliximab / adalimumab / certolizumab pegol / golimumab (Claim 14)
- Etanercept (Claim 15)

This induction-step structure is broad enough to capture many real-world CIU combination strategies, but it also introduces a practical claim-construction burden: the induction agent must be capable of decreasing those cellular metrics and the regimen must satisfy the claim’s relationship between induction and dexpramipexole.

Initial vs maintenance regimen (Claims 18–20)

Claim 18: dexpramipexole has an initial dosing regimen followed by maintenance.
Claims 19–20 give dose bands for both initial and maintenance selected from:
- 50 mg to 1,500 mg/day
- 150 mg to 300 mg/day
- 300 mg to 500 mg/day
- 300 mg to 600 mg/day

This helps the patentee cover “titration then upkeep” protocols common in drug development.

Route limitation variants (Claims 21–22)

Claim 21: oral administration.
Claim 22: topical administration.

Route claim dependence can matter for infringement mapping if dexpramipexole formulations are administered only in one route in commercial or clinical practice.

Where is the claim strength highest (and lowest)?

Highest strength: “dexpramipexole + CIU” methods

Claim 1 is narrow on the active ingredient. If a competitor’s CIU therapy uses different active, the method claim is not implicated at the composition level (unless there is cross-claiming through inducement, but method claims generally require the claimed administering).

Highest strength: specific regimens with fixed doses

Claims 5, 16, and 17 create specific target embodiments:

150 mg twice/day
75 mg twice/day
300 mg twice/day

If clinical use concentrates around these exact regimens, enforcement leverage rises materially because infringement can be mapped to a concrete regimen.

Weakest aspects: dependence on broad ranges and claim construction

The broad dose ranges in Claims 2–3, and regimen ranges in Claims 19–20, increase coverage but also increase the chance of prosecution history and claim construction disputes about:

what “therapeutically effective” means in a CIU method context,
whether out-of-range dosing can avoid dependent claims,
and how courts interpret “administering comprises” (whether literal inclusion or claim coverage requires precise matching).

The range width (e.g., 1 mg to 1,000 mg/day) also reduces practical design-around deterrence if a competitor operates outside only some sub-ranges.

Weakest aspects: combination “induction step” and biological capability language

The induction-step claims (Claims 6–7) are broad, but they depend on a functional framing:

“capable of decreasing” specific cell levels/activation.

In infringement analysis, functional capability can become a contested factual issue when the induction agent is not demonstrably used to modulate those exact biological endpoints in CIU, even if the agent is generally immunomodulatory.

How does this claim set create design-around options?

Because the claims are anchored on dexpramipexole, the most direct design-around is to use:

a different active ingredient (strongest),
a formulation/route that avoids oral or topical if only one is used commercially (Claim 21 vs 22),
or a regimen that avoids the enumerated dosing/frequency combinations in dependent claims (Claims 4, 5, 16, 17, 18–20).

The most “covered” area is daily dosing within the listed ranges; the easiest avoided area is being outside the enumerated dependent claim selections.

A practical “freedom-to-operate” posture for a developer hinges on whether a competitor can truthfully characterize CIU treatment and dexpramipexole dosing strategy as outside the dependent claim selections while still using dexpramipexole itself.

What is the competitive and patent landscape shape implied by these claims?

The claim set itself signals the main competitive vectors:

Other CIU actives targeting mast cell/basophil/eosinophil biology
Biologic add-ons (anti-IgE, IL-5 axis, IL-4/IL-13 axis, TNF inhibitors)
Induction + maintenance dosing frameworks
Route-specific commercialization (oral vs topical)

Even without enumerating each relevant US patent publication in the record, the dependent claims outline the likely field crowdedness:

Omalizumab, dupilumab, lebrikizumab, anti-IL-5/IL-5R agents, TNF inhibitors, imatinib-like kinase inhibitors, and steroid/NSAID backgrounds are historically well-developed classes in immunology.
The novelty in US 10,195,183 is not the existence of these agents, but rather the method claim coupling of CIU treatment with dexpramipexole, plus a dosing and induction framework.

Claim-by-claim “enforcement map” (what an accused protocol would need)

The table below converts the claims into a checklist.

Claim	What must be practiced to infringe	Practical “litigation hook”
1	CIU treatment + administer dexpramipexole at a therapeutically effective amount	Does the use case qualify as CIU; does dosing meet “effective” standard
2	Claim 1 + dosing/day selected from the enumerated bands	Where does the competitor’s daily dose sit relative to each band
3	Claim 1 + daily dose meets selected minimum(s)	Minimum thresholds are often easier to compare to label/regimen
4	Claim 1 + specific administration schedule among listed options	Calendar-hour schedule and dosing frequency
5	Claim 1 + about 150 mg twice/day	High mapping value if that regimen appears in filings/labels
6	Claim 1 + induction step using an agent capable of decreasing listed mast/basophil/eosinophil parameters	Whether “induction” is used and whether it meets the functional capability framing
7	Claim 1 + induction agent from the enumerated list	Constrains induction agent selection to the listed genuses
8–15	Claim 7 + specific exemplar selection	Narrows further to specific named agents
16	Claim 1 + about 75 mg twice/day	If the product’s daily total corresponds to 150 mg/day split into two doses
17	Claim 1 + about 300 mg twice/day	If competitor uses 600 mg/day split
18	Claim 1 + initial followed by maintenance	Clinical protocol sequence (initiation then ongoing dosing)
19–20	Claim 18 + initial/maintenance dosing/day within enumerated ranges	Regimen-specific daily dose bands
21	Claim 1 + oral administration	Route-specific design around if only one route is used
22	Claim 1 + topical administration	Same route avoidance logic

What does this imply for R&D planning and investment screening?

If you want to compete on dexpramipexole for CIU

Your biggest exposure is any protocol that matches Claim 1 plus one or more dependent claim selections (especially fixed regimens: Claims 5, 16, 17).
If your clinical program uses oral or topical routes, it may not help to differentiate unless you can show you are outside the enumerated route dependence and dosing schedules.

If you want to compete without triggering the method claims

Avoiding dexpramipexole entirely is the simplest structural option.
If using dexpramipexole is unavoidable, a regimen design strategy would focus on:
- selecting dosing and schedules that avoid the dependent claim options, and
- avoiding induction-step combinations that fall inside Claims 6–15.

Key Takeaways

US 10,195,183 is a dexpramipexole-centered CIU method patent with an enforcement spine in Claim 1, then multiple dependent claims that lock in dosing bands, frequency schedules, and specific dose regimens.
The most enforcement-relevant dependent claims are Claims 5, 16, 17, 18–20 because they map cleanly to clinical protocols (exact twice-daily doses and initial/maintenance frameworks).
The induction-step additions (Claims 6–15) broaden the competitive capture of combination therapies, but they can become factual disputes due to the “capable of decreasing” functional framing and the requirement that an “induction step” is actually practiced.
The most robust design-around is not using dexpramipexole; partial design-around via dosing schedule and induction agent selection is theoretically possible, but it must be tight to evade enumerated dependent claim options.

FAQs

Is the patent limited to chronic idiopathic urticaria only?
Yes. The claims explicitly require treating chronic idiopathic urticaria.
Does the patent cover any dexpramipexole dosing?
No. While Claim 1 uses “therapeutically effective amount,” dependent claims enumerate specific daily dose bands and schedules that can narrow coverage to particular regimens.
Which dependent claims are the most specific for enforcement?
Claims that fix exact regimens: Claim 5 (about 150 mg twice/day), Claim 16 (about 75 mg twice/day), Claim 17 (about 300 mg twice/day), and regimen structure claims 18–20.
Can combination therapy trigger infringement under this patent?
Yes. Claims 6–15 add an “induction step” using a therapeutic agent capable of decreasing mast/basophil/eosinophil levels or activation, including specific listed biologics and small molecules.
Do the route claims matter for infringement analysis?
They can. Claims 21–22 add oral or topical administration dependence, so route choices can influence whether particular claim embodiments are practiced.

References

[1] United States Patent 10,195,183. Claims text provided in prompt (Claim 1–22 as listed).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	August 24, 1998	⤷ Start Trial	2037-08-14
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998	⤷ Start Trial	2037-08-14
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999	⤷ Start Trial	2037-08-14
Immunex Corporation	ENBREL	etanercept	Injection	103795	September 27, 2004	⤷ Start Trial	2037-08-14
Immunex Corporation	ENBREL	etanercept	Injection	103795	February 01, 2007	⤷ Start Trial	2037-08-14
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	September 14, 2017	⤷ Start Trial	2037-08-14
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,195,183

Summary for Patent: 10,195,183